Evidence map›Paper›PMID 37370814›Full record

ArticleCancers2023

Taxifolin Inhibits Breast Cancer Growth by Facilitating CD8+ T Cell Infiltration and Inducing a Novel Set of Genes including Potential Tumor Suppressor Genes in 1q21.3.

Xiaozeng Lin, Ying Dong, Yan Gu, Anil Kapoor, Jingyi Peng, Yingying Su, Fengxiang Wei, Yanjun Wang, Chengzhi Yang, Armaan Gill and 2 more

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 2 countries.

Xiaozeng LinDepartment of Surgery, McMaster University, Hamilton, ON L8S 4K1, Canada.
Ying DongDepartment of Surgery, McMaster University, Hamilton, ON L8S 4K1, Canada.
Yan GuDepartment of Surgery, McMaster University, Hamilton, ON L8S 4K1, Canada.
Anil KapoorDepartment of Surgery, McMaster University, Hamilton, ON L8S 4K1, Canada.ORCID 0000-0001-9180-8029
Jingyi PengDepartment of Surgery, McMaster University, Hamilton, ON L8S 4K1, Canada.
Yingying SuDepartment of Surgery, McMaster University, Hamilton, ON L8S 4K1, Canada.
Fengxiang WeiThe Genetics Laboratory, Longgang District Maternity and Child Healthcare Hospital of Shenzhen City, Shenzhen 518174, China.
Yanjun WangJilin Jianwei Songkou Biotechnology Co., Ltd., Changchun 510664, China.
Chengzhi YangBenda International INC., Ottawa, ON K1X 0C1, Canada.
Armaan GillDepartment of Surgery, McMaster University, Hamilton, ON L8S 4K1, Canada.ORCID 0000-0001-8066-8235
Sandra Vega NeiraDepartment of Surgery, McMaster University, Hamilton, ON L8S 4K1, Canada.
Damu TangDepartment of Surgery, McMaster University, Hamilton, ON L8S 4K1, Canada.ORCID 0000-0002-3282-9521
St. Joseph's Hospital · CAShenzhen Maternity and Child Healthcare Hospital · CN

Funding

Industrial funding with the source details included in the manuscript NA
6 · The paper itself

Abstract

Taxifolin inhibits breast cancer (BC) via novel mechanisms. In a syngeneic mouse BC model, taxifolin suppressed 4T-1 cell-derived allografts. RNA-seq of 4T-1 tumors identified 36 differentially expressed genes (DEGs) upregulated by taxifolin. Among their human homologues, 19, 7, and 2 genes were downregulated in BCs, high-proliferative BCs, and BCs with high-fatality risks, respectively. Three genes were established as tumor suppressors and eight were novel to BC, including

Indexed as

biomarkerbreast cancerimmunosuppressive microenvironmentoverall survivaltaxifolin

Identifiers

PMID37370814
PMCPMC10296577
OpenAlexW4381462903

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.